PRCTHealthcare · Medical DevicesThe 15 Wall Street analysts covering PROCEPT BioRobotics Corp. hold a median 12-month price target of $21 — +17.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores PROCEPT BioRobotics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (71): The business earns solid, repeatable profits on what it owns.
Momentum (17): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.1% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $30 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $30 → $23 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | $35 → $25 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $34 → $28 |
| 5 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 5 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 28 July 2026 | UBS | Assumes | Neutral | $20 |
| 6 July 2026 | Truist Securities | Downgrade | Hold | $30 → $25 |
| 6 July 2026 | Truist Securities | Downgrade | Hold | — |
| 24 June 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 11 June 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 30 Apr 2026 | Piper Sandler | Reiterates | Overweight | — |
| 6 Mar 2026 | Baird | Initiates | Neutral | — |
| 2 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 26 Feb 2026 | B of A Securities | Downgrade | Underperform | — |
| 26 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 26 Feb 2026 | Oppenheimer | Downgrade | Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, PROCEPT BioRobotics Corp. returned −48.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 40% of US stocks
Cheaper than 31% of US stocks
Cheaper than 83% of US stocks
Higher than 68% of US stocks
Higher than 58% of US stocks
Higher than 79% of US stocks
Higher than 19% of US stocks
Higher than 13% of US stocks
Higher than 27% of US stocks
Higher than 23% of US stocks
Higher than 84% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PROCEPT BioRobotics Corp. has a market value of $1.0B and an enterprise value of $852.4M.
Revenue in the twelve months to 30 June 2026: $337.3M. The latest quarter grew 19.3% year on year.
Net income over the same four quarters: −$109.8M, a −32.5% net margin.
Diluted earnings per share, trailing twelve months: $−1.94.
Free cash flow in the twelve months to 30 June 2026: −$84.9M.
Trailing P/E: −10.2×; forward P/E: −14.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.74%, paying out 0% of earnings.
PROCEPT BioRobotics Corp. employs 888 people — $380K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PROCEPT BioRobotics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PROCEPT BioRobotics said it will report its third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day.
Why it matters — PRCT watchers can note the date and time when the company plans to release results and discuss them with management.
The DJS Law Group has reminded investors of a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The law firm is contacting investors regarding their rights in the case.
Why it matters — A securities class action lawsuit against the company introduces legal and reputational risk that PRCT watchers would want to monitor.
Rosen Law Firm, a global investor rights law firm, reminded purchasers of PROCEPT BioRobotics Corporation common stock during the Class Period of February 28, 2024 through February 25, 2026 of the September 22, 2026 lead plaintiff deadline in a securities fraud lawsuit.
Why it matters — PRCT watchers would care because the company faces a securities fraud lawsuit with an upcoming lead plaintiff deadline that investors who purchased during the Class Period may wish to consider.
Glancy Prongay Wolke & Rotter LLP reminded PROCEPT BioRobotics investors of the September 22, 2026 deadline to file a lead plaintiff motion in a class action securities fraud lawsuit. The lawsuit covers investors who acquired PRCT securities between February 28, 2024 and February 25, 2026.
Why it matters — PRCT shareholders who purchased during the Class Period face an upcoming deadline related to an active securities fraud lawsuit against the company.
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation on behalf of purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026. The firm is encouraging investors to contact it before September 22, 2026.
Why it matters — The company faces a class action lawsuit covering a two-year class period, which could carry legal and financial implications for PROCEPT.
The 15 Wall Street analysts covering PROCEPT BioRobotics Corp. have a median 12-month price target of $21, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering PROCEPT BioRobotics Corp., 5 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PROCEPT BioRobotics Corp. 37 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, PROCEPT BioRobotics Corp. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (71 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +17.1% from the last close, and Ticker Nerd's factor model ranks PROCEPT BioRobotics Corp. 37 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PROCEPT BioRobotics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.
PROCEPT BioRobotics Corp. returned -48.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology.
The most recent item we track (GlobeNewsWire, 12 Oct 2026): "PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026". PROCEPT BioRobotics said it will report its third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System, both designed for image-guided, minimally invasive urologic procedures. Its core offering is Aquablation therapy, a robotic treatment approach used primarily for benign prostatic hyperplasia and related lower urinary tract symptoms. PROCEPT BioRobotics also supports its systems with consumables, service, and clinical workflow tools that help hospitals and urology practices deliver precise, patient-specific care. The company serves healthcare providers in the United States and selected international markets, positioning itself within the medical device and surgical robotics segments of the healthcare industry.
CEO Mr. Larry L. Wood · 888 employees · United States · https://www.procept-biorobotics.com
